At 7.1% CAGR, the Asia Pacific Coagulation Analyzers Market is projected to be worth US$ 891.91 million by 2028, says Business Market Insights 

According to Business Market Insights’ research, the Asia Pacific coagulation analyzers market was valued at US$ 591.16 million in 2022 and is expected to reach US$ 891.91 million by 2028, registering a CAGR of 7.1% from 2022 to 2028. Increasing prevalence of blood disorders and rising cardiovascular diseases are the critical factors attributed to the Asia Pacific coagulation analyzers market expansion.

A coagulation analyzer is a device that measures and evaluates the speed of clot formation or clot coagulation. It provides a fast, simple way to measure blood platelet levels and thrombolin and thromboplastin levels accurately. Thus, the increasing prevalence of blood disorders is driving the Asia Pacific coagulation analyzers market growth.

On the contrary, high costs and stringent regulations associated with coagulation analyzers hampers the Asia Pacific coagulation analyzers market.

Based on product, the Asia Pacific coagulation analyzers market is segmented into clinical laboratory analyzers and point-of-care testing analyzers. The clinical laboratory segment held 67.8% share of Asia Pacific coagulation analyzers market in 2022, amassing US$ 400.93 million. It is projected to garner US$ 584.27 million by 2028 to expand at 6.5% CAGR during 2022–2028.

Based on test, the Asia Pacific coagulation analyzers market is segmented into prothrombin time testing, fibrinogen testing, activated clotting time testing, activated partial thromboplastin time testing, d-dimer testing, platelet function tests, anti-factor xa tests, heparin and protamine dose response tests for act, and others. The prothrombin time testing segment held 52.7% share of Asia Pacific coagulation analyzers market in 2022, amassing US$ 311.29 million. It is projected to garner US$ 469.73 million by 2028 to expand at 7.1% CAGR during 2022–2028.

Based on technology, the Asia Pacific coagulation analyzers market is segmented into optical technology, mechanical technology, electrochemical technology, and other technologies. The optical technology segment held 60.7% share of Asia Pacific coagulation analyzers market in 2022, amassing US$ 358.88 million. It is projected to garner US$ 546.37 million by 2028 to expand at 7.3% CAGR during 2022–2028.

Based on end users, the Asia Pacific coagulation analyzers market is segmented into hospitals, clinical laboratories, point-of-care testing, and others. The clinical laboratories segment held 59.6% share of Asia Pacific coagulation analyzers market in 2022, amassing US$ 352.29 million. It is projected to garner US$ 537.17 million by 2028 to expand at 7.3% CAGR during 2022–2028.

Based on country, the Asia Pacific coagulation analyzers market has been categorized into China, India, Japan, Australia, South Korea, and the Rest of the Asia Pacific. Our regional analysis states that China captured 30.4% share of Asia Pacific coagulation analyzers market in 2022. It was assessed at US$ 179.97 million in 2022 and is likely to hit US$ 274.89 million by 2028, exhibiting a CAGR of 7.3% during the forecast period.

Key players dominating the Asia Pacific coagulation analyzers market are Abbott Laboratories; Danaher Corp; F. Hoffmann-La Roche Ltd; Horiba Ltd.; Maccura Biotechnology Co Ltd; Nihon Kohden Corp; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthcare GmbH; Sysmex Corporation; and Thermo Fisher Scientific Inc, among others.

• In March 2022; Mindray Launched the BC-700 Series, a Compact, Integrated CBC & ESR Hematology Analyzer for Small-to-mid Sized Labs. It incorporates both complete blood count (CBC) and erythrocyte sedimentation rate (ESR) tests.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com